Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the Fit Biotech Oy and Bracknor Investment, Fit Biotech’s board of directors has approved Bracknor’s request relating to the funding programme to convert €30,000 worth of Convertible Notes into the Company’s K shares.
Due to the conversion of the Convertible Notes, Fit issues 454,070 new K shares to Bracknor with the conversion price of €0.067405 per share.
Fit Biotech noted that as a result of the issue of the new K shares, the total number of shares in the company will increase to 43,922,609 shares, and its share capital will be increased by €29,999.94. After the issue of the new K shares, Fit’s shares will be divided in share series of 43,852,145 K shares, 5,229 A shares and 65,235 D shares.